Dust Networks, Inc.
https://en.wikipedia.org/wiki/Dust_Networks
CEO Joy Weiss 2011 interview (MIT alum)
https://www.youtube.com/watch?v=3xjXDiySVDA
Biography:
Ms. Joy Weiss serves as President, Chief Executive Officer & Board Member at Tempo (Electrical Equipment). She served as Chief Executive Officer and President at Inviso. Ms. Joy Weiss serves as President, Dust Networks at Linear Technology. Joy was CEO of Dust Networks when it was acquired by Linear Technology in 2011. Joy has also served on the boards of several private companies, including Saraide, Glimmerglass, and Vigilent. She holds a BSEE from the Massachusetts Institute of Technology.
CTO: Chief Technology Officer of Dusk Networks, Inc.
https://en.wikipedia.org/wiki/Kristofer_Pister
https://en.wikipedia.org/wiki/Aluminium#Environmental_effects
https://en.wikipedia.org/wiki/Aluminium_powder
https://coastaluminum.com/
https://coastaluminum.com/locations/
https://www.dynavax.com/about/#management
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996, and is headquartered in Emeryville, CA.
Ryan Spencer is Chief Executive Officer of Dynavax, where he leads the company’s mission to help protect the world against infectious diseases. He first joined Dynavax in 2005 and served in positions with increasing responsibility across finance, investor relations, and corporate strategy, before becoming Senior Vice President of the commercial organization. Mr. Spencer has been instrumental in leading the approval and commercialization of the company’s differentiated hepatitis B vaccine – HEPLISAV-B® – and leveraging the company’s proprietary CpG 1018® adjuvant for development of multiple COVID-19 vaccines and advancing a diversified vaccine candidate pipeline. Prior to joining Dynavax, he served as Assistant Controller at QRS Corporation and as a member of the audit practice at Ernst & Young. Mr. Spencer is an active member of the Biotechnology Innovation Organization (BIO). He earned a Bachelor of Arts in Business Economics from University of California, Santa Barbara.
Dr. Janssen was appointed Chief Medical Officer and Vice President, Clinical Development in July 2013. He previously served as Dynavax's Vice President, Medical Affairs and Senior Director, Clinical Development. Prior to joining Dynavax in 2010, Dr. Janssen was Vice President, Medical Affairs at Gilead from 2008 to 2010 where he was responsible for oversight of physician and health care provider education focused on HIV and hepatitis B therapies. Until 2008, Dr. Janssen spent 23 years at the US Centers for Disease Control and Prevention (CDC), most recently as the Director of the Division of HIV/AIDS Prevention from 2000 to 2008. Under his leadership, CDC first explored HIV treatment as a mode of HIV prevention and launched several of the earliest Phase 3 trials of pre-exposure prophylaxis for HIV. Dr. Janssen received a Bachelor of Arts degree with Honors in Humanities from Stanford University and his M.D. degree from the University of Southern California. He is a neurologist with training in virology at the University of Pennsylvania. Dr. Janssen has been the beneficiary of numerous honors and awards during his career. He has published over 130 scientific articles in a variety of journals and has served as a reviewer for leading scientific journals.
https://www.tpsaviation.com/
https://en.wikipedia.org/wiki/Bauxite_mining_in_the_United_States
https://en.wikipedia.org/wiki/Gilead_Sciences
